Enlivex Ltd. Ordinary Shares

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.